The 340B Drug Pricing Program, established by Congress in 1992, allows safety-net hospitals and clinics to purchase outpatient prescription drugs at significant discounts from manufacturers. This program, designed to support providers serving low-income and uninsured patients, is funded not by direct federal subsidies but by mandatory discounts as a condition of participation in Medicare and Medicaid. Over the past three decades, the program has expanded dramatically, with over half of U.S. hospitals now participating and discounted purchases reaching $81.4 billion in 2024, leading to controversy over hospital margins and drug pricing. AI
RANK_REASON Article explains a policy and its controversy without new primary information.
- 340B Drug Pricing Program
- Medicaid
- Medicare
- Pharmaceutical Research and Manufacturers of America
- Us Congress
- U.S.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
